Is Akcea Therapeutics Incorporated (NASDAQ:AKCA) a Buy? The Stock Reported Less Sellers

November 14, 2017 - By Vivian Currie

 Is Akcea Therapeutics Incorporated (NASDAQ:AKCA) a Buy? The Stock Reported Less Sellers

The stock of Akcea Therapeutics Incorporated (NASDAQ:AKCA) registered a decrease of 0.28% in short interest. AKCA’s total short interest was 3.25M shares in November as published by FINRA. Its down 0.28% from 3.26 million shares, reported previously. With 308,800 shares average volume, it will take short sellers 11 days to cover their AKCA’s short positions.

About 19,573 shares traded. Akcea Therapeutics Inc (NASDAQ:AKCA) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Akcea Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $1.15 billion. The Firm is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It currently has negative earnings. The Company’s drugs, volanesorsen, AKCEA-APO-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis).

Akcea Therapeutics Inc (NASDAQ:AKCA) Ratings Coverage

Among 3 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 5 analyst reports since August 8, 2017 according to SRatingsIntel. As per Tuesday, October 31, the company rating was maintained by Stifel Nicolaus. As per Tuesday, November 7, the company rating was maintained by Stifel Nicolaus. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, August 8. BMO Capital Markets initiated the stock with “Buy” rating in Tuesday, August 8 report.

More recent Akcea Therapeutics Inc (NASDAQ:AKCA) news were published by: Globenewswire.com which released: “Akcea Therapeutics to Hold Third Quarter 2017 Financial Results Webcast” on October 23, 2017. Also Streetinsider.com published the news titled: “Akcea Therapeutics (AKCA) Begins AKCEA-ANGPTL3-LRx Phase 2 Program in Patients …” on November 13, 2017. Globenewswire.com‘s news article titled: “Akcea to Present at Stifel 2017 Healthcare Conference” with publication date: November 07, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.